RED BLOOD CELL TRANSFUSION IN PATIENTS WITH PLACENTA ACCRETA SPECTRUM: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v9i8.1789Keywords:
Red blood cells transfusion, Transfusion, Placenta accretaAbstract
Introduction: Placenta accreta spectrum (PAS) is associated with high maternal morbidity and mortality, mostly due to postpartum haemorrhage caused by aberrant placental-myometrial separation. In many instances of PAS, haemorrhage necessitates blood transfusion.
Objective: To assess the utilisation of red blood cells in patients diagnosed with placenta accreta spectrum during the process of childbirth.
Methods: A systematic review of literature published between 2003 and August 3, 2023 was performed across several databases including PubMed, Cochrane Library, and Google Scholar. Duplicate publications, review articles, and incomplete articles were excluded.
Results: The databases search identified a total of 13,613 articles (Table 1) and resulted in 13,500 articles after duplicates removed. Of these, 13,420 articles were excluded due to non-original study and titles and abstract not represented the focus of interest; and resulting in 80 articles for screening process. Articles not evaluating the focus of interest and articles in which full-text are not available are excluded, resulting in 25 articles for evaluation of eligibility criteria. Among them, 21 articles given were not specified for RBCs transfusion and did not give sufficient details. Hence, we found 4 appropriate studies included
Conclusion: Based on the studies included in this review, we are unable to recommend the minimum of units of red blood cells that should be available before delivery for patients with placenta accreta spectrum. Future studies in the form of large clinical trials is required to study the minimum of RBCs units for PAS patients before delivery, to better inform future guidelines for predelivery blood ordering and transfusion support.
References
Committee R, No O. Obstetric Care Consensus No. 7: Placenta Accreta Spectrum. Obstet Gynecol. 2018;132(6):E259–75.
Jauniaux E, Ayres-de-Campos D, Duncombe G, Klaritsch P, Chantraine F, Kingdom J, et al. FIGO consensus guidelines on placenta accreta spectrum disorders: Introduction. Int J Gynecol Obstet. 2018;140(3).
Silver RM, Branch DW. Placenta Accreta Spectrum. N Engl J Med. 2018;378(16):1529–36.
Enste R, Cricchio P, Dewandre PY, Braun T, Leonards CO, Niggemann P, et al. Placenta Accreta Spectrum Part II: Hemostatic considerations based on an extended review of the literature. J Perinat Med [Internet] 2023;51(4):455–67. Available from: https://doi.org/10.1515/jpm-2022-0233
Committee on Obstetric Practice. Committee opinion no. 529: placenta accreta. Obstet Gynecol. 2012;120(1).
Cui R, Li M, Lu J, Bai H, Zhang Z. Management strategies for patients with placenta accreta spectrum disorders who underwent pregnancy termination in the second trimester: A retrospective study. BMC Pregnancy Childbirth. 2018;18(1).
Morlando M, Sarno L, Napolitano R, Capone A, Tessitore G, Maruotti GM, et al. Placenta accreta: Incidence and risk factors in an area with a particularly high rate of cesarean section. Acta Obstet Gynecol Scand. 2013;92(4).
Shellhaas CS, Gilbert S, Landon MB, Varner MW, Leveno KJ, Hauth JC, et al. The frequency and complication rates of hysterectomy accompanying cesarean delivery. Obstet Gynecol. 2009;114(2):224–9.
Stotler B, Padmanabhan A, Devine P, Wright J, Spitalnik SL, Schwartz J. Transfusion requirements in obstetric patients with placenta accreta. Transfusion. 2011;51(12):2627–33.
Nieto-Calvache AJ, Palacios-Jaraquemada JM, Osanan G, Cortes-Charry R, Aryananda RA, Bangal VB, et al. Lack of experience is a main cause of maternal death in placenta accreta spectrum patients. Acta Obstet Gynecol Scand. 2021;100(8).
Schwickert A, van Beekhuizen HJ, Bertholdt C, Fox KA, Kayem G, Morel O, et al. Association of peripartum management and high maternal blood loss at cesarean delivery for placenta accreta spectrum (PAS): A multinational database study. Acta Obstet Gynecol Scand. 2021;100(S1).
Seoud MA, Nasr R, Berjawi GA, Zaatari GS, Seoud TM, Shatila AS, et al. Placenta accreta: Elective versus emergent delivery as a major predictor of blood loss. J Neonatal Perinatal Med. 2017;10(1):9–15.
Setyawan N, Permana S. Massive transfusion in cesarean section patients with placenta accreta: A case series. Bali J Anesthesiol. 2021;5(3):191–4.
Munoz JL, Kimura AM, Xenakis E, Jenkins DH, Braverman MA, Ramsey PS, et al. Whole blood transfusion reduces overall component transfusion in cases of placenta accreta spectrum: a pilot program. J Matern Neonatal Med [Internet] 2022;35(25):6455–60. Available from: https://doi.org/10.1080/14767058.2021.1915275
Thang NM, Anh NTH, Thanh PH, Linh PT, Cuong TD. Emergent versus planned delivery in patients with placenta accreta spectrum disorders: A retrospective study. Med (United States). 2021;100(51):E28353.
Roeca C, Little SE, Carusi DA. Pathologically diagnosed placenta accreta and hemorrhagic morbidity in a subsequent pregnancy. Obstet Gynecol. 2017;129(2):321–6.
Padmanabhan A, Schwartz J, Spitalnik SL. Transfusion Therapy in Postpartum Hemorrhage. Vol. 33, Seminars in Perinatology. 2009.
Burtelow M, Riley E, Druzin M, Fontaine M, Viele M, Goodnough LT. How we treat: Management of lifethreatening primary postpartum hemorrhage with a standardized massive transfusion protocol. Transfusion. 2007;47(9).
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
